For many investors, the main point of stock picking is to generate higher returns than the overall market. But if ...

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against Prem Watsa’s other ...

SCHD ETF effectively combines dividend income and dividend growth, while offering investors a reduced Expense Ratio. Click ...

Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

Beam Therapeutics Inc . (NASDAQ:BEAM), a $2.1 billion market cap pioneer in the field of precision genetic medicines through base editing, is set to present new data from its ongoing BEACON Phase 1/2 ...

Take a look at three predictions for the year ahead for pharma executives considering AI implementation and adoption. For AI to live up to its potential, pharma executives need to not simply invest in ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that ...